Location of Repository

Safety of using genetic engineering biological agents in rheumatoid arthritis

By N V Chichasova and E L NasonovN V Chichasova and E L Nasonov

Abstract

The paper reviews the current trials of the safety of using genetic engineering biological agents (GEBA) in patients with rheumatoid arthritis. It is stated that before its start, GEBA therapy calls for thorough screening of patients to rule out communicable diseases (including tuberculosis) or a high risk for infections (chronic shin ulcers, severe diabetes mellitus, persistent lung infection, and the presence of a urinary catheter), cancer, and severe visceral diseases. The baseline liver status, a cardiovascular risk, neutropenia in response to basic anti-inflammatory drugs (BAID) should be also borne in mind. It is noted that when patients are correctly selected and possible adverse reactions are monitored, GEBA therapy is not worse tolerated than is BAID therapy

Topics: ревматоидный артрит, генно-инженерные биологические препараты, Medicine, R
Publisher: IMA-PRESS LLC
Year: 2010
OAI identifier: oai:doaj.org/article:1740392211b349e4b2fdfd55b7eeb3bb
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2310-158X (external link)
  • https://doaj.org/toc/1996-7012 (external link)
  • http://mrj.ima-press.net/mrj/a... (external link)
  • https://doaj.org/article/17403... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.